About us
The case for partnership
The many challenges facing modern society have much in common. They all require solutions to increasingly complex problems – affecting more people – using fewer resources. Whether feeding the world, addressing environmental issues, or improving the health of a growing and ageing population with increasingly unhealthy lifestyles, demand soars and resources dwindle.
Delivering more with less has two important consequences. Firstly, those addressing societal challenges must be creative. Secondly, the task is beyond any one person, organization, or country.
Lygature exists to foster, drive and support collaboration for the development of new medical solutions for patients
In the case of health, multimorbidity (co-existence of two or more chronic conditions) is becoming the norm rather than the exception as life expectancy increases. Chronic conditions such as cardiovascular diseases, diabetes and cancer are typically multifactorial (caused by a combination of genetic, environmental and lifestyle factors). It all means that diagnosis and treatment must be increasingly multidisciplinary so it is more precise, less invasive, and more cost-effective.
Dealing with complexity
New solutions increasingly combine approaches – for example the use of companion diagnostics that provide essential information for safer and more efficacious prescription of drugs. However, developing such solutions is risky, time-consuming, and expensive. It requires collaboration across disciplines such as medicine, biology, genetics, software engineering, and others. Activities also involve different industry sectors, including medical devices and (bio)pharmaceuticals, and also involve diverse stakeholders such as government, patients, doctors, and health insurers.
No single research group or company can handle such complexity alone, but together it becomes possible with close collaboration between public and private partners. Lygature exists to foster, drive and support such collaboration – to help all stakeholders thrive as their roles change:
| Organization | Changing role |
|---|---|
| Large companies | Moving into open innovation and reducing R&D investment |
| SMEs | Partnering with others and climbing the value chain |
| Academia | Dealing with increased pressure to show added value to society |
| Government | Addressing new political and economic developments |
| Patient organizations | Articulating the voice of the patient more effectively |
| Health foundations | Ensuring that public and private funding is well spent |
| Regulatory bodies | Balancing risk and patient benefit as the environment changes |